As the world grapples with the possibility of a significant Ebola outbreak, research institutions and pharmaceutical companies are racing against time to develop new vaccines targeting the Bundibugyo species of the virus. Three pioneering candidates are currently in advanced development: one spearheaded by the International Aids Vaccine Initiative (IAVI), another by Moderna, and a promising effort from the University of Oxford.
The urgency of this endeavor has never been clearer; with nearly 250 fatalities reported, the situation is escalating rapidly in the Democratic Republic of the Congo (DRC) and its neighbors. According to IAVI, the outbreak may become the worst on record, reminiscent of the catastrophic West African epidemic from 2014 to 2016 that infected approximately 29,000 individuals and claimed over 11,000 lives.
"This is clearly threatening to be as severe an outbreak as that, if not even worse," stated Dr. Mark Feinberg, head of IAVI. He emphasized that the development of effective vaccines and other countermeasures is an immediate priority. The Coalition for Epidemic Preparedness Innovations (CEPI), which is financing these research initiatives, echoed his sentiment, noting that "every day counts" in the fight against this deadly virus.
Currently, more than 1,000 suspected cases are being monitored in DRC, with nine confirmed cases spilling over into Uganda. The outbreak's spread in a conflict-affected region—marked by limited healthcare resources—raises significant alarm among public health experts.
"We have never recorded so many cases so soon in an outbreak. The situation is deeply alarming," warned Médecins Sans Frontières (Doctors Without Borders), further underscoring the critical need for vaccines tailored to specific Ebola species.
While there is an existing vaccine for the Zaire species, this current threat stems from the less common Bundibugyo strain. Although previously observed only twice, Bundibugyo lacks an approved vaccine, making the work of researchers all the more urgent. IAVI is focusing on a modified version of the Zaire vaccine to combat Bundibugyo. So far, initial animal testing has shown promising results, with the experimental jab providing close to 100% protection in monkeys.
Feinberg expressed cautious optimism regarding their progress but indicated that it could take an estimated seven to nine months to prepare for clinical trials. "We are working diligently to accelerate those timelines," he noted.
Following a similar roadmap, Moderna is harnessing its mRNA technology, previously deployed to combat COVID-19, to expedite the development of a Bundibugyo vaccine. "We are committed to acting with urgency and scientific rigor to ensure the potential vaccine reaches the communities that need it most," stated Stéphane Bancel, CEO of Moderna.
The University of Oxford is also leveraging lessons learned during the pandemic, developing its own Ebola vaccine that is expected to enter clinical trials in just two to three months. Each vaccine seeks to train the immune system to recognize the Bundibugyo glycoprotein, a vital component for fighting off the virus.
"With Bundibugyo virus spreading rapidly and no licensed vaccines available, every day is critical in the race against this deadly disease," emphasized Dr. Richard Hatchett, CEO of CEPI. Adding to the optimism, Dr. Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization (WHO), stated, "A Bundibugyo vaccine could help control this epidemic and bolster preparedness for future outbreaks."
As these developments unfold, the medical community remains on high alert, with hopes pinned on the success of these innovative vaccine candidates to stem the tide of this urgent public health crisis.
Source: BBC News
Source: BBC Health
